In Situ Hybridization市場：製品（消耗品、機器、ソフトウェア）、技術（DNA FISH、RNA FISH、PNA FISH、CISH）、用途（癌、免疫学、神経科学、細胞学）、エンドユーザー（病院、医薬品、バイオテクノロジー、CROs）別 - 2027年までの世界市場予測

In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospitals, Pharma, Biotech, CROs) – Global Forecast to 2027

in situ hybridizationの世界市場は、2022年の15億米ドルから2027年には28億米ドルに達すると予測され、予測期間中のCAGRは12.6%となります。コンパニオン診断製品は、がんの診断と治療を改善するための大きな可... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年11月3日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	193	272	英語

サマリー

in situ hybridizationの世界市場は、2022年の15億米ドルから2027年には28億米ドルに達すると予測され、予測期間中のCAGRは12.6%となります。コンパニオン診断製品は、がんの診断と治療を改善するための大きな可能性を示しています。FISHベースのバイオマーカーは、形態学と遺伝子増幅を同時に評価できるため、コンパニオン診断の開発において重要な役割を果たしています。このため、コンパニオン診断検査において、ISHベースの消耗品の採用が進んでいます。
"2021年のISH消耗品市場収益では、キット＆試薬セグメントが最も高いシェアを占めている"
ISH市場は、消耗品、機器、ソフトウェアの3つの主要製品に分類されます。ISH消耗品市場はさらに、キット＆試薬、プローブ、アクセサリーに分類される。キットの利点は、使いやすいこと、すぐに使える試薬や抗体があること、抗原に対する抗体の感度が最適化されていること、エラーの可能性が低いことです。このため、がん患者の治療中に特定の薬剤の適用を確認するために使用される診断ツールにキットの使用が促進されました。
"2021年のISH市場で最大の収益シェアを占めたのは病院と診断ラボ"
エンドユーザーに基づき、世界のin situハイブリダイゼーション市場は、病院＆診断ラボ、学術・研究機関、CRO、製薬・バイオテクノロジー企業に区分されます。病院＆診断ラボラトリー部門は、2021年に最も高い収益をあげています。患者人口の増加、病院で実施される臨床検査に対するメディケア償還の増加、高度な診断検査の出現などが、このエンドユーザー区分の成長を促進する主な要因である。

"アジア太平洋地域in situハイブリダイゼーション市場において最も成長率の高い国"
in situハイブリダイゼーション市場は、北米、欧州、アジア太平洋地域、RoWに区分されます。アジア太平洋地域のin situハイブリダイゼーション市場は、予測期間中に最も高いCAGRで成長すると予想されています。この地域の国々における経済成長、大規模な人口基盤、慢性疾患の有病率の上昇、生活水準の向上、質の高い医療に対する需要の高まり、医療支出の増加、政府の取り組み、組織診断検査の使用に関する意識などが、アジア太平洋地域の市場成長を促す主な要因となっています。
本レポートのために実施した主なインタビューは、以下のように分類されます。

- 回答者別供給側：80％、需要側：20
- 指定者別Cレベル：25％、Dレベル：20％、その他：55
- 地域別北米：50％、欧州：20％、アジア太平洋：20％、RoW：10
報告書に掲載された企業リスト
- アボット社 (米国)
- アブカム社（英国）
- アブノバコーポレーション (台湾)
- アジレント・テクノロジー株式会社（米国）
- バイオSB社（米国）
- バイオケアメディカル社（米国）
- バイオキャットGmbH（ドイツ）
- バイオジェネックス・ラボラトリーズ（米国）
- バイオ・ラッド・ラボラトリーズ（米国）
- バイオテクネ・コーポレーション（米国）
- バイオビュー社（イスラエル）
- クリエイティブバイオアレイ（米国）
- ダナハー (米)
- エンゾ・バイオケム（米国）
- F. ホフマン・ラ・ロシュ社（スイス）
- ジーンメッドバイオテクノロジーズ社（米国）
- メルクKGaA（ドイツ）
- ネオジェノミクス・ラボラトリーズ（米国）
- オプジェン（米国）
- オックスフォード・ジーン・テクノロジー社（英国）
- パーキンエルマー社（米国）
- QIAGEN N.V.(オランダ)
- サーモフィッシャーサイエンティフィック（米国）
- ZytoVision GmbH（ドイツ）
調査範囲
本レポートは、in situ hybridization市場の詳細なイメージを提供します。製品、技術、アプリケーション、エンドユーザー、地域など、さまざまなセグメントにおける市場規模および今後の成長性を推定することを目的としています。また、主要な市場プレイヤーの詳細な競合分析、企業プロファイル、最近の開発、主要な市場戦略も掲載しています。
レポート購入の主なメリット
本レポートは、in situ hybridization市場全体とそのセグメントに関する収益数の最も近い概算を提供することで、市場リーダー/新規参入者を支援するものです。また、利害関係者が競争状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、動向、機会、課題に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS & EXCLUSIONS 32
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.4 YEARS CONSIDERED 33
1.5 CURRENCY CONSIDERED 33
1.6 LIMITATIONS 33
1.7 STAKEHOLDERS 33
1.8 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 35
2.1.2 PRIMARY DATA 36
FIGURE 2 BREAKDOWN OF PRIMARIES: IN SITU HYBRIDIZATION MARKET 37
2.2 MARKET ESTIMATION METHODOLOGY 37
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION) 37
FIGURE 4 IN SITU HYBRIDIZATION MARKET SIZE (USD MILLION) 38
FIGURE 5 IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022−2027) 38
FIGURE 6 IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES 39
2.3 MARKET DATA ESTIMATION & TRIANGULATION 40
2.3.1 DATA TRIANGULATION 40
FIGURE 7 DATA TRIANGULATION METHODOLOGY 40
2.4 INDUSTRY INSIGHTS 41
2.5 RESEARCH ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
FIGURE 8 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 42
FIGURE 9 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 43
FIGURE 10 FLUORESCENT IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021 43
FIGURE 11 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 44
FIGURE 12 IN SITU HYBRIDIZATION MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 44
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF IN SITU HYBRIDIZATION MARKET 45
4 PREMIUM INSIGHTS 46
4.1 IN SITU HYBRIDIZATION MARKET OVERVIEW 46
FIGURE 14 GROWING FOCUS ON COMPANION DIAGNOSTICS AND RISING INCIDENCE OF CANCER & GENETIC DISORDERS TO DRIVE MARKET 46
4.2 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET 46
FIGURE 15 CONSUMABLES TO COMMAND LARGEST SHARE IN 2021 46
4.3 IN SITU HYBRIDIZATION MARKET: BY REGION AND END USER, 2022 VS. 2027 (USD MILLION) 47
FIGURE 16 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT TO GROW AT HIGHEST CAGR IN NORTH AMERICA 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 17 IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 48
TABLE 1 IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS 49
5.2.1 DRIVERS 49
5.2.1.1 Rising incidence of genetic disorders and cancer 49
5.2.1.2 Growing awareness of companion diagnostics 49
5.2.2 OPPORTUNITIES 50
5.2.2.1 Emerging economies 50
5.2.3 CHALLENGES 50
5.2.3.1 Shortage of skilled professionals 50
5.3 PORTER’S FIVE FORCES ANALYSIS 50
TABLE 2 IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS 50
5.3.1 THREAT OF NEW ENTRANTS 51
5.3.2 THREAT OF SUBSTITUTES 51
5.3.3 BARGAINING POWER OF BUYERS 51
5.3.4 BARGAINING POWER OF SUPPLIERS 51
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 51
5.4 SUPPLY CHAIN ANALYSIS 52
FIGURE 18 IN SITU HYBRIDIZATION MARKET: SUPPLY CHAIN 52
5.5 VALUE CHAIN ANALYSIS 53
FIGURE 19 VALUE CHAIN ANALYSIS OF THE IN SITU HYBRIDIZATION MARKET 53
5.6 ECOSYSTEM ANALYSIS 54
FIGURE 20 IN SITU HYBRIDIZATION MARKET: ECOSYSTEM ANALYSIS 54
5.7 KEY CONFERENCES & EVENTS (2020─2022) 54
5.7.1 IN SITU HYBRIDIZATION CONFERENCES (2022) 54
TABLE 3 IN SITU HYBRIDIZATION CONFERENCES (2022) 54
5.7.2 IN SITU HYBRIDIZATION CONFERENCES (2021) 55
5.7.3 IN SITU HYBRIDIZATION CONFERENCES (2020) 55
TABLE 4 IN SITU HYBRIDIZATION CONFERENCES (2020) 55
5.8 REGULATORY ANALYSIS (IN SITU HYBRIDIZATION) 55
5.8.1 FDA APPROVALS 55
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 55
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 55
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57
5.9 PRICING ANALYSIS 57
TABLE 9 PRICING ANALYSIS OF IN SITU PRODUCTS 57
5.9.1 IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TREND FOR TREATMENT 58
6 IN SITU HYBRIDIZATION MARKET, BY PRODUCT 59
6.1 INTRODUCTION 60
TABLE 10 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 60
6.2 CONSUMABLES 60
TABLE 11 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 60
TABLE 12 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY REGION, 2020–2027 (USD MILLION) 61
TABLE 13 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION) 61
TABLE 14 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION) 61
TABLE 15 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION) 62
6.2.1 PROBES 62
6.2.1.1 Preference for direct localization of DNA/RNA sequences using probes 62
TABLE 16 IN SITU HYBRIDIZATION MARKET FOR PROBES, BY REGION, 2020–2027 (USD MILLION) 62
TABLE 17 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION) 63
TABLE 18 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION) 63
TABLE 19 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION) 63
6.2.2 KITS & REAGENTS 64
6.2.2.1 Growing focus on companion diagnostics to drive demand 64
TABLE 20 IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY REGION, 2020–2027 (USD MILLION) 64
TABLE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 64
TABLE 22 EUROPE: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 23 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 65
6.2.3 ACCESSORIES 65
TABLE 24 IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 25 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION) 66
TABLE 26 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION) 66
TABLE 27 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION) 67
6.3 INSTRUMENTS 67
6.3.1 RISING DEMAND FOR AUTOMATED SYSTEMS TO SUPPORT MARKET GROWTH 67
TABLE 28 IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY REGION, 2020–2027 (USD MILLION) 67
TABLE 29 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 68
TABLE 30 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 68
TABLE 31 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 68
6.4 SOFTWARE 69
6.4.1 RISING NEED FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET 69
TABLE 32 IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION) 69
TABLE 33 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 69
TABLE 34 EUROPE: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 35 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 70
7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY 71
7.1 INTRODUCTION 72
TABLE 36 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 72
7.2 FLUORESCENT IN SITU HYBRIDIZATION 72
TABLE 37 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 72
TABLE 38 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 39 NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 40 EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 41 ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
7.2.1 DNA FLUORESCENT IN SITU HYBRIDIZATION 74
7.2.1.1 Rising need to ensure stability of genetic material to drive market 74
TABLE 42 DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 43 NORTH AMERICA: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 44 EUROPE: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 45 ASIA PACIFIC: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
7.2.2 RNA FLUORESCENT IN SITU HYBRIDIZATION 76
7.2.2.1 Increasing biomedical research activity to support market growth 76
TABLE 46 RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION) 76
TABLE 47 NORTH AMERICA: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 48 EUROPE: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 49 ASIA PACIFIC: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
7.2.3 PNA FLUORESCENT IN SITU HYBRIDIZATION 77
7.2.3.1 Utilization of PNA FISH for infectious disease control to drive market 77
TABLE 50 PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 51 NORTH AMERICA: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 52 EUROPE: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 53 ASIA PACIFIC: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79
7.3 CHROMOGENIC IN SITU HYBRIDIZATION 79
7.3.1 COST-EFFECTIVE ALTERNATIVE TO FISH TO SUPPORT MARKET GROWTH 79
TABLE 54 CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 55 NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 56 EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 57 ASIA PACIFIC: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION 81
8.1 INTRODUCTION 82
TABLE 58 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 82
8.2 CANCER DIAGNOSTICS 82
8.2.1 INCREASING UTILIZATION OF FISH IN COMPANION DIAGNOSTICS TO DRIVE MARKET 82
TABLE 59 IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 60 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 61 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 62 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 83
8.3 CYTOLOGY 84
8.3.1 IDENTIFICATION OF CYTOGENETIC ALTERATIONS TO DRIVE DEMAND FOR FISH 84
TABLE 63 IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 64 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 65 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 66 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 85
8.4 INFECTIOUS DISEASE DIAGNOSTICS 86
8.4.1 RISING NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET 86
TABLE 67 IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 86
TABLE 68 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 69 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 70 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 87
8.5 NEUROSCIENCE 88
8.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR ISH 88
TABLE 71 IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 72 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 73 EUROPE: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 74 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION) 89
8.6 IMMUNOLOGY 90
8.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET 90
TABLE 75 IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 76 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 77 EUROPE: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 78 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 91
9 IN SITU HYBRIDIZATION MARKET, BY END USER 92
9.1 INTRODUCTION 93
TABLE 79 IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 93
9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES 93
9.2.1 HOSPITAL-BASED LABS ARE ACCESSIBLE AND OFFER RAPID TEST RESULTS 93
TABLE 80 IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 81 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 82 EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 83 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 95
9.3 ACADEMIC & RESEARCH INSTITUTES 95
9.3.1 INCREASING R&D ACTIVITIES FOR CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET GROWTH 95
TABLE 84 IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 85 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 86 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 87 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 96
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 97
9.4.1 RISING DEMAND FOR PRECISION TREATMENTS TO DRIVE MARKET 97
TABLE 88 IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 89 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 90 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 91 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 98
9.5 CONTRACT RESEARCH ORGANIZATIONS 98
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 98
TABLE 92 IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 99
TABLE 93 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 94 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 95 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 100
10 IN SITU HYBRIDIZATION MARKET, BY REGION 101
10.1 INTRODUCTION 102
TABLE 96 IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION) 102
10.2 NORTH AMERICA 103
FIGURE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT 103
TABLE 97 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 98 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 104
TABLE 99 NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 100 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 105
TABLE 101 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 105
TABLE 102 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027(USD MILLION) 105
TABLE 103 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 106
10.2.1 US 106
10.2.1.1 Rising government funding for life science research to drive market 106
TABLE 104 US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 106
TABLE 105 US: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 107
TABLE 106 US: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 107
TABLE 107 US: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 107
TABLE 108 US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 109 US: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 108
10.2.2 CANADA 108
10.2.2.1 Increasing investments in genomics research to drive market 108
TABLE 110 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 109
TABLE 111 CANADA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 112 CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 109
TABLE 113 CANADA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 110
TABLE 114 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 115 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
10.3 EUROPE 111
TABLE 116 EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 117 EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 111
TABLE 118 EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 119 EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 112
TABLE 120 EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 112
TABLE 121 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 122 EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 113
10.3.1 GERMANY 113
10.3.1.1 Rising demand for technologically advanced diagnostic procedures to drive market 113
TABLE 123 GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 113
TABLE 124 GERMANY: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 125 GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 114
TABLE 126 GERMANY: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114
TABLE 127 GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 128 GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 115
10.3.2 FRANCE 115
10.3.2.1 Growing investments in proteomics and genomics to drive market 115
TABLE 129 FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 116
TABLE 130 FRANCE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 131 FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 116
TABLE 132 FRANCE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 117
TABLE 133 FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 134 FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 117
10.3.3 UK 118
10.3.3.1 Growing focus on cancer research to drive market for ISH 118
TABLE 135 UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 118
TABLE 136 UK: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 137 UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 119
TABLE 138 UK: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 119
TABLE 139 UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 140 UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 120
10.3.4 REST OF EUROPE (ROE) 120
TABLE 141 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 120
TABLE 142 REST OF EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 143 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 121
TABLE 144 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 121
TABLE 145 REST OF EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 146 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
10.4 ASIA PACIFIC 123
FIGURE 22 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT 123
TABLE 147 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 148 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 124
TABLE 149 ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 150 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 125
TABLE 151 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 125
TABLE 152 ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 153 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
10.4.1 JAPAN 126
10.4.1.1 Rising focus on personalized diagnostics products to support market growth 126
TABLE 154 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 126
TABLE 155 JAPAN: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 156 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 127
TABLE 157 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127
TABLE 158 JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 159 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
10.4.2 CHINA 128
10.4.2.1 Rising annual R&D investments to drive market demand for FISH and CISH-based kits 128
TABLE 160 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 129
TABLE 161 CHINA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 162 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 129
TABLE 163 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 130
TABLE 164 CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 165 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
10.4.3 INDIA 131
10.4.3.1 Collaborations between hospitals and diagnostics centers for laboratory services to drive market 131
TABLE 166 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 131
TABLE 167 INDIA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 168 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 132
TABLE 169 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 132
TABLE 170 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 171 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 133
10.4.4 REST OF ASIA PACIFIC 133
TABLE 172 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 133
TABLE 173 REST OF ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 174 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 134
TABLE 175 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 134
TABLE 176 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 177 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 135
10.5 REST OF THE WORLD (ROW) 136
TABLE 178 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION) 136
TABLE 179 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 136
TABLE 180 REST OF THE WORLD: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 181 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 137
TABLE 182 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 137
TABLE 183 REST OF THE WORLD: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 184 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 138
11 COMPETITIVE LANDSCAPE 139
11.1 INTRODUCTION 139
11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT-TO-WIN ANALYSIS 140
FIGURE 23 IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 140
11.3 MARKET SHARE ANALYSIS 141
FIGURE 24 IN SITU HYBRIDIZATION MARKET: MARKET SHARE ANALYSIS FOR KEY PLAYERS (2021) 141
11.4 REVENUE SHARE ANALYSIS 142
FIGURE 25 REVENUE ANALYSIS FOR KEY COMPANIES (2019−2021) 142
11.5 COMPANY EVALUATION QUADRANT 143
11.5.1 STARS 143
11.5.2 EMERGING LEADERS 143
11.5.3 PERVASIVE PLAYERS 143
11.5.4 PARTICIPANTS 143
FIGURE 26 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021) 144
11.6 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 145
11.6.1 PROGRESSIVE COMPANIES 145
11.6.2 STARTING BLOCKS 145
11.6.3 RESPONSIVE COMPANIES 145
11.6.4 DYNAMIC COMPANIES 145
FIGURE 27 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION QUADRANT (2021) 146
11.6.5 COMPETITIVE BENCHMARKING 147
11.6.5.1 In situ hybridization market: Startups/SMEs 147
TABLE 185 LIST OIN SITU HYBRIDIZATION MARKET: STARTUPS/SMES 147
11.6.5.2 In situ hybridization market: Competitive benchmarking of key players [startups/SMEs) 148
TABLE 186 IN SITU HYBRIDIZATION MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES] 148
11.7 COMPETITIVE SCENARIO AND TRENDS 149
11.7.1 DEALS 149
TABLE 187 IN SITU HYBRIDIZATION MARKET: DEALS 149
11.7.2 PRODUCT LAUNCHES 149
TABLE 188 IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES 149
12 COMPANY PROFILES 151
12.1 KEY COMPANIES 151
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT 151
TABLE 189 ABBOTT: BUSINESS OVERVIEW 151
FIGURE 28 ABBOTT: COMPANY SNAPSHOT 152
TABLE 190 ABBOTT: PRODUCTS OFFERED 152
12.1.2 F. HOFFMANN-LA ROCHE AG 154
TABLE 191 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW 154
FIGURE 29 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT 155
TABLE 192 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 155
TABLE 193 F. HOFFMANN-LA ROCHE LTD: PRODUCT APPROVALS 156
12.1.3 THERMO FISHER SCIENTIFIC INC. 157
TABLE 194 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 157
TABLE 195 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 158
12.1.4 DANAHER 161
TABLE 196 DANAHER: BUSINESS OVERVIEW 161
FIGURE 31 DANAHER: COMPANY SNAPSHOT 161
TABLE 197 DANAHER: PRODUCTS OFFERED 162
TABLE 198 PRODUCT APPROVALS 162
12.1.5 AGILENT TECHNOLOGIES, INC. 164
TABLE 199 AGILENT TECHNOLOGIES, INC: BUSINESS OVERVIEW 164
TABLE 200 AGILENT TECHNOLOGIES, INC: PRODUCTS OFFERED 165
12.1.6 BIOCARE MEDICAL, LLC 167
TABLE 201 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW 167
TABLE 202 BIOCARE MEDICAL, LLC: PRODUCTS OFFERED 167
12.1.7 BIO-TECHNE CORPORATION 169
TABLE 203 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 169
TABLE 204 BIO-TECHNE: PRODUCT LAUNCHES 170
12.1.8 QIAGEN N.V. 171
TABLE 205 QIAGEN N.V.: BUSINESS OVERVIEW 171
TABLE 206 QIAGEN N.V.: PRODUCTS OFFERED 172
12.1.9 MERCK KGAA 173
TABLE 207 MERCK KGAA: BUSINESS OVERVIEW 173
TABLE 208 MERCK KGAA: PRODUCTS OFFERED 174
12.1.10 PERKINELMER 175
TABLE 209 PERKINELMER: BUSINESS OVERVIEW 175
TABLE 210 PERKINELMER: PRODUCTS OFFERED 176
12.1.11 ENZO BIOCHEM 177
TABLE 211 ENZO BIOCHEM: BUSINESS OVERVIEW 177
FIGURE 37 ENZO BIOCHEM: COMPANY SNAPSHOT 177
TABLE 212 ENZO BIOCHEM: PRODUCTS OFFERED 178
12.1.12 BIO-RAD LABORATORIES 179
TABLE 213 BIO-RAD LABORATORIES: BUSINESS OVERVIEW 179
TABLE 214 BIO-RAD LABORATORIES: PRODUCTS OFFERED 180
12.1.13 ABNOVA CORPORATION 181
TABLE 215 ABNOVA CORPORATION: BUSINESS OVERVIEW 181
TABLE 216 ABNOVA CORPORATION: PRODUCTS OFFERED 181
12.1.14 BIOGENEX LABORATORIES 182
TABLE 217 BIOGENEX LABORATORIES: BUSINESS OVERVIEW 182
TABLE 218 BIOGENEX LABORATORIES: PRODUCTS OFFERED 182
12.1.15 OPGEN 184
TABLE 219 OPGEN: BUSINESS OVERVIEW 184
TABLE 220 OPGEN INC: PRODUCTS OFFERED 185
12.1.16 BIO SB 186
TABLE 221 BIO SB: BUSINESS OVERVIEW 186
TABLE 222 BIO SB: PRODUCTS OFFERED 186
12.1.17 ABCAM 187
TABLE 223 ABCAM: BUSINESS OVERVIEW 187
TABLE 224 ABCAM: PRODUCTS OFFERED 188
12.1.18 ZYTOMED SYSTEMS GMBH 189
TABLE 225 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW 189
TABLE 226 ZYTOMED SYSTEMS: PRODUCTS OFFERED 189
12.1.19 NEOGENOMICS LABORATORIES 190
TABLE 227 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW 190
TABLE 228 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED 191
12.1.20 BIOVIEW 192
TABLE 229 BIOVIEW: BUSINESS OVERVIEW 192
TABLE 230 BIOVIEW: PRODUCTS OFFERED 192
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 193
12.2.1 GENEMED BIOTECHNOLOGIES 193
TABLE 231 GENEMED BIOTECHNOLOGIES: BUSINESS OVERVIEW 193
12.2.2 CREATIVE BIOARRAY 193
TABLE 232 CREATIVE BIOARRAY: BUSINESS OVERVIEW 193
12.2.3 BIOCAT GMBH 194
TABLE 233 BIOCAT GMBH: BUSINESS OVERVIEW 194
12.2.4 OXFORD GENE TECHNOLOGY 194
TABLE 234 OXFORD GENE TECHNOLOGY: BUSINESS OVERVIEW 194
12.2.5 ZYTOVISION 194
TABLE 235 ZYTOVISION: BUSINESS OVERVIEW 194
13 APPENDIX 195
13.1 DISCUSSION GUIDE 195
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 198
13.3 CUSTOMIZATION OPTIONS 200
13.4 RELATED REPORTS 200
13.5 AUTHOR DETAILS 201

ページTOPに戻る

Table of Contents

Summary

The global in situ hybridization market is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 12.6% during the forecast period. Companion diagnostic products showcase a significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously. This has increased the adoption of ISH-based consumables across companion diagnostic tests.
“The kits & reagents segment accounted for the highest share in the ISH consumables market revenue for the year 2021”
The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.
“Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021”
Based on the end users the global in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.

“Asia Pacific: The fastest-growing country in the in situ hybridization market”
The in situ hybridization market is segmented into North America, Europe, Asia Pacific, RoW. The in situ hybridization market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the countries of this region, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: C-level - 25%, D-level - 20%, and Others - 55%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report:
• Abbott (US)
• Abcam (UK)
• Abnova Corporation (Taiwan)
• Agilent Technologies, Inc. (US)
• Bio SB Inc. (US)
• Biocare Medical, LLC (US)
• BioCat GmbH (Germany)
• BioGenex Laboratories (US)
• Bio-Rad Laboratories (US)
• Bio-Techne Corporation (US)
• BioView (Israel)
• Creative Bioarray (US)
• Danaher (US)
• Enzo Biochem (US)
• F. Hoffmann-La Roche AG (Switzerland)
• GeneMed Biotechnologies Inc. (US)
• Merck KGaA (Germany)
• NeoGenomics Laboratories (US)
• OpGen (US)
• Oxford Gene Technology (UK)
• PerkinElmer Inc. (US)
• QIAGEN N.V. (Netherlands)
• Thermo Fisher Scientific (US)
• ZytoVision GmbH (Germany)
Research Coverage:
This report provides a detailed picture of the in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（consumables）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（consumables）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?